Jinxin Fertility nets HK$1.3bn from share sale

By Jonathan Breen
02 Feb 2021

Mainland-based Jinxin Fertility Group raised HK$1.27bn ($163.5m) in fresh equity on Monday after issuing a chunk of new shares.

The issuer specialises in a particular niche of the healthcare industry, providing assisted reproductive services (ARS) such as in vitro fertilisation (IVF) treatments. It operates in China, southeast Asia and the US.

It tapped equity investors for the first time since listing in June 2019, Dealogic data ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial